Spectral AI Q2 EPS beats estimate, sales miss consensus
Spectral AI's Q2 results show an EPS beat driven by non-cash warrant gains, despite a significant miss on revenue estimates due to declining government contract reimbursements. The company maintains strong cash reserves ahead of commercial launch.
*this image is generated using AI for illustrative purposes only.
Spectral AI, Inc. (NASDAQ: MDAI) reported second-quarter earnings per share (EPS) of $(0.13), beating the analyst consensus estimate of $(0.14). However, the Dallas-based medical diagnostics company’s quarterly sales of $3.524 million missed the $4.145 million estimate by 14.98 percent. The results reflect a 58.06 percent improvement in losses compared to $(0.31) per share in the same period last year, while revenue declined 30.42 percent from $5.065 million in Q2 2025.
The beat on EPS was driven primarily by non-operational factors rather than core business performance. Spectral AI attributes its improved bottom line to a $0.7 million non-cash benefit from changes in the fair value of its warrant liability. This gain offset operational headwinds, including a compression in gross margin to 31.6% from 45.2% year-over-year. The margin contraction stems from cost-share provisions in the follow-on development phase of the company’s Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA).
Revenue decline aligns with anticipated decreases in reimbursed costs under the BARDA contract as the scope of work narrowed following FDA clearance. Additionally, revenue from other U.S. government contracts fell as Spectral AI completed performance obligations under its Department of Defense contract via the Medical Technology Enterprise Consortium (MTEC). Despite the miss on sales estimates, the company secured a pivotal operational milestone: the U.S. Food and Drug Administration (FDA) granted De Novo clearance for Spectral AI’s DeepView System for burn indication in May 2026.
Operating expenses rose 23.2% to $5.4 million from $4.4 million in Q2 2025, reflecting the company’s transition toward commercial activities. General and administrative expenses increased by $0.5 million due to equity awards, while selling and marketing activities grew by $0.3 million ahead of first commercial sales. The balance sheet remains fortified with $14.0 million in cash as of June 30, 2026, supported by a $6.5 million draw under an existing credit facility with Avenue Capital Group.
Key Financial Metrics vs Estimates
| Metric | Actual | Estimate | Variance |
|---|---|---|---|
| EPS | $(0.13) | $(0.14) | Beat |
| Revenue | $3.524 million | $4.145 million | Miss |
What the Numbers Show
The divergence between the EPS beat and the revenue miss highlights the significant impact of financing-related accounting items on Spectral AI’s results. While the core business faced headwinds—with gross margin contracting and operating expenses rising—the reported net loss was substantially mitigated by the warrant liability gain. In the prior year’s comparable period, this line item represented a $5.4 million expense. This volatility underscores that the improvement in net loss is not yet reflective of operational profitability but rather of favorable market-driven adjustments to derivative liabilities.
How will the recent FDA De Novo clearance for the DeepView System impact Spectral AI's revenue trajectory and gross margins in upcoming quarters?
What is the expected timeline for Spectral AI to achieve operational profitability given the current contraction in gross margins and rising operating expenses?
How might the expiration of performance obligations under the Department of Defense contract affect future government-related revenue streams?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
